The growth would primarily better revenues from its drug Copaxone as projected by Natco Pharma’s marketing partner Mylan and also improved performance the rest of the world based on new product launches.
New Delhi: Natco Pharma expects India, Brazil and Canada markets to be its revenue drivers during the current financial year, recording growth of 30 per cent to 40 per cent, according to a top company executive.
The India business alone was likely to grow by about 15 per cent to 20 per cent, Natco Vice-Chairman and Chief Executive Officer Rajeev Nannapaneni has said.
“…the second driver will be Brazil, so Brazil did not do well for many years, so we had some very good launches this year and so that should drive earnings,” he said replying to a query during a recently held Earnings Call of the company.
At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news.
MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at firstname.lastname@example.org Contact no. 011-43720751